[go: up one dir, main page]

EA201991464A1 - АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ

Info

Publication number
EA201991464A1
EA201991464A1 EA201991464A EA201991464A EA201991464A1 EA 201991464 A1 EA201991464 A1 EA 201991464A1 EA 201991464 A EA201991464 A EA 201991464A EA 201991464 A EA201991464 A EA 201991464A EA 201991464 A1 EA201991464 A1 EA 201991464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synuclein
aggregates
sinuclein
antibody
application
Prior art date
Application number
EA201991464A
Other languages
English (en)
Other versions
EA039807B1 (ru
Inventor
Чжинхён Ан
Сонвон Ан
Донин Ким
Ынсиль Сон
Джехён Ом
Сан Хун Ли
Сын-Джэ Ли
Тэ Кён Ким
Мин Сон Чой
Вонкю Ю
Джехо Чон
Джухи Ким
Джинвон Чон
Ёнчжу Ким
Ёнгю Сон
Бёндже Сон
Original Assignee
ЭйБиЭл БИО ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйБиЭл БИО ИНК. filed Critical ЭйБиЭл БИО ИНК.
Priority claimed from PCT/KR2018/000239 external-priority patent/WO2018128454A1/ko
Publication of EA201991464A1 publication Critical patent/EA201991464A1/ru
Publication of EA039807B1 publication Critical patent/EA039807B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

В настоящем изобретении раскрыты антитела к α-синуклеину, предпочтительно распознающие агрегаты α-синуклеина. Антитела по данному изобретению связываются с агрегатами α-синуклеина с высокой аффинностью и специфичностью и ингибируют накопление или внутриклеточный транспорт агрегатов α-синуклеина и, таким образом, могут использоваться для определения, диагностики и/или лечения или предупреждения различных заболеваний, вызванных накоплением агрегатов α-синуклеина.
EA201991464A 2017-01-06 2018-01-05 Антитело к -синуклеину и его применение EA039807B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443151P 2017-01-06 2017-01-06
KR1020180001641A KR102014066B1 (ko) 2017-01-06 2018-01-05 항 α-syn 항체 및 그 용도
PCT/KR2018/000239 WO2018128454A1 (ko) 2017-01-06 2018-01-05 항 α-SYN 항체 및 그 용도

Publications (2)

Publication Number Publication Date
EA201991464A1 true EA201991464A1 (ru) 2020-01-15
EA039807B1 EA039807B1 (ru) 2022-03-16

Family

ID=63048162

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991464A EA039807B1 (ru) 2017-01-06 2018-01-05 Антитело к -синуклеину и его применение

Country Status (7)

Country Link
US (1) US12049493B2 (ru)
JP (1) JP6908709B2 (ru)
KR (1) KR102014066B1 (ru)
CN (1) CN110494445B (ru)
BR (1) BR112019013953A2 (ru)
EA (1) EA039807B1 (ru)
MX (1) MX2019008029A (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6908709B2 (ja) 2017-01-06 2021-07-28 エービーエル バイオ インコーポレイテッド 抗α−ｓｙｎ抗体およびその使用
BR112020009707A2 (pt) * 2017-11-17 2020-10-13 Abl Bio Inc. anticorpos para a-sinucleína e usos dos mesmos
EP4403218A3 (en) 2017-12-14 2024-11-06 ABL Bio, Inc. Bispecific antibody to a-syn/igf1r and use thereof
WO2020009551A1 (ko) 2018-07-06 2020-01-09 바이오그래핀 주식회사 신경단백질의 비정상적 섬유화 또는 응집과 관련된 질환 치료제로서의 그래핀 양자점
CN112368002B (zh) 2018-07-06 2023-05-30 生物石墨烯有限公司 用作与神经蛋白异常纤维化或凝聚相关疾病治疗剂的石墨烯量子点
US20210347868A1 (en) * 2018-10-19 2021-11-11 Gabriel Pascual Anti-synuclein antibodies
KR102691493B1 (ko) 2019-06-14 2024-08-05 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
CN114173814A (zh) * 2019-07-11 2022-03-11 古德T细胞有限公司 用于预防、改善或治疗免疫检查点抑制剂耐药癌症的组合物
EP4379054A1 (en) 2021-07-27 2024-06-05 Stand Therapeutics Co., Ltd. Peptide tag and nucleic acid encoding same
CN119080938B (zh) * 2023-06-05 2025-06-24 东莞市朋志生物科技有限公司 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒
WO2025053658A1 (ko) * 2023-09-06 2025-03-13 주식회사 굳티셀 친화도 성숙이 이루어진 신규 항체

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5260503A (en) 1987-06-11 1993-11-09 Pioneer Hi-Bred International, Inc. Hybrid sorghum plant and seed 8358
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
CZ301712B6 (cs) 2001-01-05 2010-06-02 Pfizer Inc. Protilátka k receptoru IGF-I a farmaceutický prípravek obsahující tuto protilátku
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
RS20060099A (en) 2003-08-13 2008-08-07 Pfizer Products Inc., Modified human igf-1r antibodies
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2006138729A2 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
AU2006301426A1 (en) 2005-10-11 2007-04-19 Ablynx N.V. NanobodiesTM and polypeptides against EGFR and IGF-IR
TWI428444B (zh) 2005-10-12 2014-03-01 Morphosys Ag 由全長人類ＨｕＣＡＬ ＧＯＬＤ-衍生之對人類ＣＤ３８有特異性之治療抗體之產生及鑑定
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
US20110014117A1 (en) 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
EP2376561B1 (en) 2008-12-23 2018-10-03 3M Innovative Properties Company Amorphous microporous organosilicate compositions
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
LT2539366T (lt) * 2010-02-26 2018-04-25 Bioarctic Ab Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
NZ724348A (en) 2010-11-30 2019-12-20 Genentech Inc Low affinity blood brain barrier receptor antibodies and uses therefor
BR112013033258B1 (pt) 2011-06-23 2022-09-20 University Of Zurich Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfasinucleína, composição e seus usos
CA2853531C (en) 2011-10-28 2020-03-10 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
EP2773957B1 (en) 2011-11-02 2017-11-29 Biogen International Neuroscience GmbH Use of an anti-alpha-synuclein antibody to diagnose an elevated level of alpha-synuclein in the brain
WO2013112945A1 (en) 2012-01-27 2013-08-01 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
SG10201702702VA (en) 2012-08-29 2017-06-29 Hoffmann La Roche Blood brain barrier shuttle
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
WO2014059442A2 (en) * 2012-10-12 2014-04-17 Arizona Board Agents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
KR20140138533A (ko) 2013-05-24 2014-12-04 한화케미칼 주식회사 항 igf-1r 단일클론 항체 및 이를 포함하는 암치료용 조성물
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
WO2015130115A1 (en) 2014-02-28 2015-09-03 Scripps Korea Antibody Institute Novel antibody specific for tspan8 and uses thereof
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
KR102355308B1 (ko) 2014-03-06 2022-01-24 내셔날 리서치 카운실 오브 캐나다 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
AU2014385801B2 (en) 2014-03-06 2020-11-12 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
WO2016061389A2 (en) * 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JP6908709B2 (ja) 2017-01-06 2021-07-28 エービーエル バイオ インコーポレイテッド 抗α−ｓｙｎ抗体およびその使用
WO2018128454A1 (ko) 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
IL272361B2 (en) 2017-08-02 2025-06-01 Stressmarq Biosciences Inc Antibodies that bind active alpha-synuclein
BR112020009707A2 (pt) 2017-11-17 2020-10-13 Abl Bio Inc. anticorpos para a-sinucleína e usos dos mesmos
EP4403218A3 (en) 2017-12-14 2024-11-06 ABL Bio, Inc. Bispecific antibody to a-syn/igf1r and use thereof
KR102691493B1 (ko) 2019-06-14 2024-08-05 에이비엘바이오 주식회사 α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도
AR125857A1 (es) 2021-05-12 2023-08-16 Abl Bio Incorporated ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS

Also Published As

Publication number Publication date
CN110494445B (zh) 2023-10-20
MX2019008029A (es) 2019-12-11
JP2020515233A (ja) 2020-05-28
KR20180081465A (ko) 2018-07-16
US20230227540A1 (en) 2023-07-20
US12049493B2 (en) 2024-07-30
JP6908709B2 (ja) 2021-07-28
KR102014066B1 (ko) 2019-10-21
CN110494445A (zh) 2019-11-22
EA039807B1 (ru) 2022-03-16
BR112019013953A2 (pt) 2020-02-11

Similar Documents

Publication Publication Date Title
EA201991464A1 (ru) АНТИТЕЛО К α-СИНУКЛЕИНУ И ЕГО ПРИМЕНЕНИЕ
EA202091540A1 (ru) Антитела к lilrb2
EA201890712A1 (ru) Антитела к про-/латентному миостатину и их применения
EA201892417A1 (ru) Антитела, распознающие тау
EA201791712A1 (ru) Антитела к транстиретину
MX2024006564A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA201992546A1 (ru) Средства на основе антител к cd33
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201791754A1 (ru) АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EA201791711A1 (ru) Антитела к транстиретину
EA201892412A1 (ru) Антитела, распознающие тау
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
EA201992091A1 (ru) Анти-c5 антитела и их применение
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201591716A1 (ru) Антитела анти-il-33 и их применение
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
MX2020004674A (es) Anticuerpos contra alfa-sinucleina y usos de los mismos.
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof